Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

被引：0

作者：

Pietanza, M. Catherine ^{[1
]}

Travis, William D. ^{[1
]}

Chan, Timothy A. ^{[1
]}

Ginsberg, Michelle S. ^{[1
]}

Kris, Andrei Holodny Mark G. ^{[1
]}

Krug, Lee M. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

PANCREAS | 2010年 / 39卷 / 02期

关键词：

D O I：

10.1097/01.mpa.0000363940.51906.5a

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：279 / 279

页数：1

共 50 条

[11] Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC)
Ardizzoni, A
Hansen, HH
Dombernowsky, P
Kaplan, S
Postmus, PE
Gamucci, T
Schaefer, B
Wanders, J
Verweij, J
EUROPEAN JOURNAL OF CANCER, 1995, 31A : 84 - 84
[12] Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer
Hall, Peter E.
Ready, Neal
Johnston, Amanda
Bomalaski, John S.
Venhaus, Ralph R.
Sheaff, Michael
Krug, Lee
Szlosarek, Peter W.
CLINICAL LUNG CANCER, 2020, 21 (06) : 527 - 533
[13] Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer
Hirose, Takashi
Nakashima, Masanao
Shirai, Takao
Kusumoto, Sojiro
Sugiyama, Tomohide
Yamaoka, Toshimitsu
Okuda, Kentaro
Ohnishi, Tsukasa
Ohmori, Tohru
Adachi, Mitsuru
LUNG CANCER, 2011, 73 (03) : 345 - 350
[14] Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
Pietanza, M. Catherine
Waqar, Saiama N.
Krug, Lee M.
Dowlati, Afshin
Hann, Christine L.
Chiappori, Alberto
Owonikoko, Taofeek K.
Woo, Kaitlin M.
Cardnell, Robert J.
Fujimoto, Junya
Long, Lihong
Diao, Lixia
Wang, Jing
Bensman, Yevgeniva
Hurtado, Brenda
de Groot, Patricia
Sulman, Erik P.
Wistuba, Ignacio I.
Chen, Alice
Fleisher, Martin
Heymach, John V.
Kris, Mark G.
Rudin, Charles M.
Byers, Lauren Averett
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2386 - +
[15] Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer
Byrne, Margaret M.
Sutamtewagul, Grerk
Zeitler, William
Mott, Sarah L.
Zamba, Gideon K. D.
Kojadinovic, Arsenije
Zhang, Jun
Abu-Hejleh, Taher
Clamon, Gerald
Furqan, Muhammad
FRONTIERS IN ONCOLOGY, 2024, 14
[16] Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC).
Hirose, T.
Shirai, T.
Kusumoto, S.
Sugiyama, T.
Yamaoka, T.
Okuda, K.
Ohmori, T.
Ohnishi, T.
Adachi, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[17] Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer
Naka, N
Kawahara, M
Okishio, K
Hosoe, S
Ogawara, M
Atagi, S
Takemoto, Y
Ueno, K
Kawaguchi, T
Tsuchiyama, T
Furuse, K
LUNG CANCER, 2002, 37 (03) : 319 - 323
[18] Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer
Kitagawa, Chiyoe
Iwasaku, Masahiro
Kogure, Yoshihito
Ando, Masahiko
Yoshioka, Hiroshige
Nishiyama, Akihiro
Watanabe, Naoki
Kunimasa, Kei
Tsubouchi, Kazuya
Oka, Saori
Saka, Hideo
IN VIVO, 2019, 33 (01): : 163 - 166
[19] Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
Heist, Rebecca Suk
Fain, Jerry
Chinnasami, Bernard
Khan, Waseem
Molina, Julian R.
Sequist, Lecia V.
Temel, Jennifer S.
Fidias, Panos
Brainerd, Valari
Leopold, Lance
Lynch, Thomas J.
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1637 - 1643
[20] A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
Kim, Yu-Jung
Keam, Bhumsuk
Ock, Chan-Young
Song, Sanghoon
Kim, Miso
Kim, Se Hyun
Kim, Ki Hwan
Kim, Jin-Soo
Kim, Tae Min
Kim, Dong-Wan
Lee, Jong Seok
Heo, Dae Seog
LUNG CANCER, 2019, 136 : 122 - 128

← 1 2 3 4 5 →